Fragment 176-191: Structure and Research Overview

Fragment 176-191 is exactly what the name says: a short synthetic peptide matching residues 176 through 191 of human growth hormone (hGH). It’s the C-terminal tail of the parent protein, snipped out and made on its own. Sounds trivial. It isn’t, because a small piece of a big protein can behave nothing like the whole thing. Below we cover what the fragment is, how it relates to hGH structurally, and what the primary literature actually measured. Everything’s linked.

What Fragment 176-191 is

Human growth hormone is a single chain of 191 amino acids. Fragment 176-191 is the stretch from position 176 to 191, a 16 residue piece off the protein’s C-terminal end, made on its own in the lab [1]. Being such a small slice of a much larger protein, it doesn’t carry hGH’s full three-dimensional fold, and that’s the question researchers keep circling back to: does a fragment this size hold onto any measurable activity from the parent, or not?

How it relates to the parent protein

To get the fragment, you have to get hGH first. The full protein is a four-helix bundle held together by disulfide bonds, and it’s been resolved in complex with its receptor, which showed how one hormone grabs receptor copies through distinct binding surfaces [4]. Residues 176 to 191 land in the C-terminal region of that fold. Pull them out and they leave the helical scaffold behind, so the free fragment is floppier, conformationally, than those same residues locked inside intact hGH. That structural context is the whole thing that separates the fragment from the hormone it comes from.

What the structural work showed

The most relevant structural study is Ogru and colleagues, who looked at the conformation of a cyclic peptide built from the C-terminal domain of human growth hormone, pairing biological and conformational analysis [1]. Work like this matters because a linear 16mer can flop through many shapes in solution, and constraining it, by cyclization for instance, is one way to ask which shapes relate to any measured activity [1]. The practical takeaway for anyone handling the fragment: its conformation isn’t fixed, and that has knock-on effects for how a reference standard behaves analytically.

What the rodent studies measured

Most of the research on this part of hGH centered on a close relative, the C-terminal construct AOD9604. Heffernan and colleagues looked at the effects of human GH and this modified C-terminal fragment on lipid metabolism after chronic exposure in obese mice and in beta-3 adrenergic receptor knockout mice [2]. A companion paper from the same group reported changes in fat oxidation in obese mice following chronic exposure to human GH or a modified C-terminal fragment [3], and earlier work from Ng and colleagues examined the molecular and cellular actions of a structural domain of hGH on lipid metabolism in Zucker fatty rats [5]. We’re stating these flatly and in past tense, because that’s what they are: specific animal-model measurements, not general conclusions about anything. The brand-free naming matters too, since the research literature uses construct identifiers, not any consumer label.

Why a fragment is studied separately

Fair question: why isolate a 16 residue slice of a 191 residue protein instead of just using the whole thing? Short answer, small peptides are easier to synthesize, cheaper to make at purity, and simpler to characterize than a full disulfide-bonded protein. They also let you ask one focused question: does this specific region carry any of the activity tied to the parent, or does that need the intact fold? For Fragment 176-191, the primary literature hasn’t fully settled that, which is part of why the honest body of work is smaller than the marketing would have you think. Yanked out of hGH’s four-helix bundle [4], these residues lose their fixed geometry, and that freedom is exactly what the conformational studies set out to probe [1].

How it’s characterized analytically

As a 16 residue synthetic peptide, Fragment 176-191 gets the standard toolkit: reversed-phase HPLC for purity, mass spectrometry for identity against the calculated mass. Because the free fragment is so flexible, analysts sometimes add spectroscopic checks when conformation actually matters to the study [1]. For how purity and identity get verified in general, see our overview of third-party tested peptides, and for where this sits in the wider peptide family, our peptide basics overview gives the structural context.

Frequently asked questions

What part of growth hormone is Fragment 176-191?

The C-terminal stretch, residues 176 to 191, of the 191 amino acid human growth hormone protein [1][4].

How long is the peptide?

Sixteen amino acids, matching positions 176 through 191 of hGH [1].

Does the fragment keep the same shape as that region in intact hGH?

No. Pulled out of the parent protein’s fold, the free fragment is flexible, which is why structural studies have used constrained versions to probe it [1].

References

1. Ogru E, Wilson JC, Heffernan M, et al. The conformational and biological analysis of a cyclic peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000. PMID 11152298
2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) […] in mice and beta(3)-AR knock-out mice. Endocrinology. 2001. PMID 11713213
3. Heffernan MA, Thorburn AW, Fam B, et al. […] human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. PMID 11673763
4. Clackson T, Ultsch MH, Wells JA, de Vos AM. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol. 1998. PMID 9571026
5. Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000. PMID 11116208